New U.S. Patents Granted for RegenLab

Thursday, September 13, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

LE-MONT-SUR LAUSANNE, Switzerland, September 13, 2018 /PRNewswire/ --

Mr. Antoine

Turzi, inventor, Regen Lab SA and RegenLab USA LLC are delighted to announce that the United States Patent and Trademark Office (USPTO) has issued two new U.S. patents covering its Platelet Rich Plasma (PRP), Bone
Marrow Concentrate (BMC) and Hyaluronic Acid (HA) technologies:

  1. Systems/methods combining PRP and HA: U.S. Patent No. 10,052,349 and
  2. Systems for the preparation of PRP and BMC, in particular tubes containing a thixotropic gel and anticoagulant: U.S. Patent No. 10,064,894.

This brings a total of six U.S. granted patents with US8,529,957, US9,833,478, US9833478, US8,945,537 and US9,517,255 on these technologies, expanding RegenLab's patent portfolio along with patents also recently granted in other jurisdictions (see figure below).

     (Photo: https://mma.prnewswire.com/media/743261/RegenLab_Figure_1.jpg )

     (Logo: https://mma.prnewswire.com/media/743260/RegenLab_Logo.jpg )

All these new patents represent a recognition by the USPTO of RegenLab's innovation, technology and efficiency. This is great news for RegenLab, its employees and partners, and justifies that RegenLab maintains its legal actions for the respect of its intellectual property rights. The stars are shining for RegenLab's team and its future.

About RegenLab 

RegenLab is a leading innovator of medical devices for the preparation of platelet rich plasma, which it markets under the well-recognized REGENLABŪ and REGENKITŪ brands. RegenLab remains committed to providing pyrogen-free devices of the highest quality and safety, as well as protecting customers through enforcement of its intellectual property rights.

Additional information about RegenLab and its patents can be found at https://www.regenlab.com/patents and http://www.RegenLabUSA.com.

SOURCE Regen Lab SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store